Literature DB >> 19891908

Management of risk factors for accelerated atherosclerosis.

Sarah Song1, Bruce Ovbiagele.   

Abstract

Atherosclerosis is a relentlessly progressive process of segmental vessel narrowing or occlusion involving several vascular beds. It accounts for the majority of strokes, which remain a global leading cause of death and long-term disability. The limited options for acute stroke therapy make stroke prevention an important therapeutic approach, particularly in patients who have already experienced stroke. Given the multifactorial pathogenesis of atherosclerotic disease, an aggressive multimodal preventive strategy is required to mitigate risk of recurrent stroke. Such a strategy would incorporate proven treatments specifically targeting the underlying disease process. A vast number of strokes could be prevented by optimal treatment of modifiable vascular risk factors. This paper presents current evidence-based management of conventional and novel vascular risk factors in patients with ischemic stroke whose underlying pathophysiologic mechanism is accelerated atherosclerosis. Therapies discussed include antithrombotics, statins, antihypertensives, and surgical/endovascular treatments.

Entities:  

Year:  2009        PMID: 19891908     DOI: 10.1007/s11940-009-0050-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  35 in total

1.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

2.  Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial.

Authors: 
Journal:  Lancet       Date:  2001-06-02       Impact factor: 79.321

3.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

4.  Ten-year survival after first-ever stroke in the perth community stroke study.

Authors:  Kate Hardie; Graeme J Hankey; Konrad Jamrozik; Robyn J Broadhurst; Craig Anderson
Journal:  Stroke       Date:  2003-07-03       Impact factor: 7.914

5.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial.

Authors:  A Halliday; A Mansfield; J Marro; C Peto; R Peto; J Potter; D Thomas
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

Review 6.  Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review.

Authors:  Parveen Rashid; Jo Leonardi-Bee; Philip Bath
Journal:  Stroke       Date:  2003-10-23       Impact factor: 7.914

7.  Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis.

Authors:  H J M Barnett; D W Taylor; R B Haynes; D L Sackett; S J Peerless; G G Ferguson; A J Fox; R N Rankin; V C Hachinski; D O Wiebers; M Eliasziw
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

8.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleight; Richard Peto
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

9.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

10.  Executive summary: standards of medical care in diabetes--2009.

Authors: 
Journal:  Diabetes Care       Date:  2009-01       Impact factor: 19.112

View more
  2 in total

Review 1.  Therapeutic approaches to drug targets in atherosclerosis.

Authors:  Prasad G Jamkhande; Prakash G Chandak; Shashikant C Dhawale; Sonal R Barde; Priti S Tidke; Ram S Sakhare
Journal:  Saudi Pharm J       Date:  2013-11-05       Impact factor: 4.330

2.  The antiatherogenic effect of bixin in hypercholesterolemic rabbits is associated to the improvement of lipid profile and to its antioxidant and anti-inflammatory effects.

Authors:  Sabrina Somacal; Cassieli G Figueiredo; Andréia Quatrin; Amanda R Ruviaro; Lisiane Conte; Paula R Augusti; Miguel Roehrs; Ione T Denardin; Jocieli Kasten; Marcelo L da Veiga; Marta M F Duarte; Tatiana Emanuelli
Journal:  Mol Cell Biochem       Date:  2015-02-22       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.